Fluorinase: A tool for the synthesis of 18F-labeled sugars and nucleosides for PET

Future Medicinal Chemistry

Volumn 1, Issue 5, 2009, Pages 865-873

  Onega, Mayca ^a   Winkler, Margit ^a   O'Hagan, David ^a  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 DEOXY 5 FLUORORIBOSE 1 PHOSPHATE F 18; 5' DEOXY 5' FLUOROADENOSINE F 18; 9 (2' DEOXY 2' FLUORO BETA DEXTRO ARABINOFURANOSYL)ADENINE F 18; ADENOSINE; ADENOSINE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BACTERIAL ENZYME; CARBON 11; FLUORINASE; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; NITROGEN 13; NUCLEOSIDE ANALOG; OXYGEN 15; PYRIMIDINE NUCLEOSIDE; RADIOPHARMACEUTICAL AGENT; RIBOSE; UNCLASSIFIED DRUG; URIDINE DERIVATIVE;

DRUG EFFICACY; DRUG SYNTHESIS; ENZYME MECHANISM; ENZYME SYNTHESIS; ESCHERICHIA COLI; FLUORINATION; HUMAN; ISOTOPE LABELING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; STREPTOMYCES;

ADENOSINE; BACTERIAL PROTEINS; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; OXIDOREDUCTASES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; STREPTOMYCES;

EID: 72149127791     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.74     Document Type: Short Survey

References (70)

1. ÓHagan D, Schaffrath C, Cobb SL, Hamilton JTG, Murphy CD. Enzyme catalysed organofluorine synthesis. Nature 416, 279 (2002).
2. Schaffrath C, Deng H, ÓHagan D. Isolation and characterisation of 5́-fluorodeoxyadenosine synthetase, a fluorination enzyme from Streptomyces cattleya. FEBS Lett. 547, 111-114 (2003).
3. Dong C, Huang F, Deng H et al. Crystal structure and mechanism of a bacterial fluorinating enzyme. Nature 427, 561-465 (2004).
4. Phelps ME, Hoffman EJ, Mullani NA, Ter-Pogissian MM. Application of annihilhation and coincidence detection to transaxial reconstruction tomography. J. Nucl. Med. 16, 210-224 (1975).
5. Muehllehner G, Karp JS. Positron emission tomography. Phy. Med. Biol. 51, 117-137 (2006).
6. Dollé F, Roeda D, Kuhnast B, Lasne M-C. Fluorine-18 chemistry for molecular imaging with PET. In: Fluorine and Health. Tressaud A, Haufe G (Eds). Elsevier, Amsterdam, The Netherlands 4-65 (2008).
7. Fowler JS. The synthesis and application of F-18 compounds in positron emission tomography. In: Organofluorine Compounds in Medicinal Chemistry and Biomedical Applications. Filler R, Kobayashi Y, Yagupolskii LM (Eds). Elsevier, Amsterdam, The Netherlands, 309-338 (1993).
8. Schiepers C. Positron emission tomography: a coming of age? Eur. J. Intern. Med. 15, 143-146 (2004).
9. Chen W. Clinical applications of PET in brain tumors. J. Nucl. Med. 48, 1468-1481 (2007).
10. Wong DF, Brašic JR. In vivo imaging of neurotransmitter systems in neuropsychiatry. Clinical Neurosci. Res. 1, 35-45 (2001).
11. Kopka K, Wagner S, Schäfers M, Faust A, Schober O, Haufe G. 18F-Labeled PETtracers for cardiological imaging. In: Fluorine and Health. Tressaud A, Haufe G (Eds). Elsevier, Amsterdam, The Netherlands 85-139 (2008).
12. Någren K, Rinne JO. Application of 18F-PET imaging for the study of Alzheimer's disease. In: Fluorine and Health. Tressaud A, Haufe G (Eds). Elsevier, Amsterdam, The Netherlands, 67-84 (2008).
13. Pike KE, Savage G, Villemagne VL et al. β-amyloid imaging and memory in non-demented individuals. Evidence for preclinical Alzheimer's disease. Brain 130, 2837-2844 (2007).
14. Rowe CC, Ng S, Ackermann U et al. Imaging β-amyloid burden in aging and dementia. Neurology 15, 1718-1725 (2007).
15. Foster NL, Heidebrink JL, Clark CM et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia Alzheimer's disease. Brain 130, 2616-2635 (2007).
16. Didelot A, Ryvlin P, Lothe A, Merlet I, Hammers A, Mauguière F. PET imaging of brain 5-HT1A receptors in the preoperative evaluation of temporal lobe epilepsy. Brain 131, 1-14 (2008).
17. Milak MS, Parsey RV, Keilp J, Oquendo MA, Malone KM, Mann JJ. Neuroanatomic correlates of psychopathologic components of major depressive disorder. Arch. Gen. Psychiatry 62, 397-408 (2005).
18. Kennedy S H, Evans KR, Krüger S et al. Changes in regional brain glucose metabolism measured by positron emission tomography after paroxetine treatment of major depression. Am. J. Psychiatry 158, 899-905 (2001).
19. Mamo D, Kapur S, Keshavan M et al. D-2 receptor occupancy olanzapine pamoate depot using positron emission tomography: an open-label study on patients with schizophrenia. Neuropsychopharmacology 33, 298-304 (2008).
20. Okubo Y, Suhara T, Suzuki K et al. Decreases prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385, 634-636 (1997).
21. Gerasimov MR, Dewey SL. Development of a GABAergic treatment for substance abuse using PET. Drug Develop. Res. 59, 240-248 (2003).
22. Lingford-Hughes AR, Davies SJC, McIver S, Williams TM, Daglish MRC, Nutt DJ. Addiction. Brit. Med. Bull. 65, 209 (2003).
23. Neves AA, Brindle KM. Assessing responses to cancer therapy using molecular imaging. Biochim. Biophys. Acta 1766, 242-261 (2006).
24. Weber WA. Use of PET for monitoring cancer therapy and predicting outcome. J. Nucl. Med. 46, 983-995 (2005).
25. Strauss LG, Conti PS. The applications of PET in clinical oncology. J. Nucl. Med. 32, 623-648 (1991).
26. Hermann K, Krause BJ. [18F]-Labeled PET and PET/CT compounds in oncology. In: Fluorine and Health. Tressaud A, Haufe G (Eds). Elsevier, Amsterdam, The Netherlands, 141-196 (2008).
27. West CML, Jones T, Price P. The potential of positron emission tomography to study anti-cancer drug resistance. Nature Rev. Cancer 4, 457-469 (2004).
28. Gupta N, Price PM, Aboagye EO. PET for in vivo pharmacokinetic and pharmocodynamic measurements. Eur. J. Cancer 38, 2094-2107 (2002).
29. Gee AD. Neuropharmacology and drug development. Br. Med. Bull. 65, 169 (2003).
30. Ido T, Wan WN, Casella V et al. Labelled 2-deoxy-d-glucose analogues. 18F-labelled 2-deoxy-2-fluoro-d-glucose, 2-deoxy-2-fluoro-d-mannose and [14C] 2-deoxy-2-fluorod-glucose. J. Label. Cmpd Radiopharm. 14, 175-183 (1978).
31. +- emitting compounds based of fluorine-18. In: Topics in Current Chemistry (Volume 2). Springer-Verlag, Berlin, Heildelberg, Germany, 201-258 (2002).
32. Cai L, Lu S, Pike VW. Chemistry with [18F] fluoride ion. Eur. J. Org. Chem. 2853-2873 (2008).
33. Isanbor C, O'Hagan D. Fluorine in medicinal chemistry: Anticancer agents. J. Fluorine Chem. 127, 303-319 (2006).
34. Le Bars D. Fluorine-18 and medical imaging. Radiopharmaceuticals for positron emission tomography J. Fluorine Chem. 127, 1488-1493 (2006).
35. Gambhir SS, Czernin J, Schwimmer J et al. A tabulated survey of the FDG PET literature. J. Nucl. Med. 42, S1-S93 (2001).
36. Phelps ME, Mazziotta JC. Positron emission tomography: human brain function and biochemistry. Science 228, 799-809 (1985).
37. Delgado-Bolton RC, Fernández-Pérez C, González- Maté A, Carreras JL. Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. J. Nucl. Med. 44, 1301-1314 (2003).
38. Som P, Atkins HL, Bandoypadhyay D et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-d-glucose (F-18): nontoxic tracer for rapid tumor detection. J. Nucl. Med. 21, 670-675 (1980).
39. Smith TAD. Mammalian hexokinases and their abnormal expression in cancer. Br. J. Biomed. Sci. 57, 170-178 (2000).
40. Schelbert HR, Hoh CK, Royal HD et al. Procedure guideline for tumor imaging using fluorine-18-FDG . J. Nucl. Med. 39, 1302-1305 (1998).
41. Varagnolo L, Stokkel MPM, Mazzi U, Pauwels EKJ. 18F-labeled radiopharmaceuticals for PET in oncology, excluding FDG. Nucl. Med. Biol. 27, 103-112 (2000).
42. Beuthien-Baumann B, Hamacher K, Oberdorfer F, Steinbach J. Preparation of fluorine-18 labelled sugars and derivatives and their application as tracer for positronemission-tomography. J. Carbohydr. Res. 327, 107-118 (2000).
43. Ishiwata K, Kimura Y, de Vries EFJ, Elsinga P. PET Tracers for mapping adenosine receptors as probes for diagnosis for CNS disorders. Cent. Nerv. Syst. Agents. Med. Chem. 7, 57-77 (2007).
44. Damaraju VL, Damaraju S, Young JD et al. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 22, 7524-7536 (2003).
45. Pennycooke M, Chaudary N, Shuralyova I, Zhang Y, Coe IR. Differential expression of human nucleoside transporters in normal and tumor tissue. Biochem. Biophys. Res. Commun. 280, 951-959 (2001).
46. Baldwin SA, Mackey JR, Cass CE, Young JD. Nucleoside transporters: molecular biology and implications for therapeutic development. Mol. Med. Today 5, 216-224 (1999).
47. Thorn JA, Jarvis SM. Adenosine transporters. Gen. Pharmac. 27, 613-620 (1996).
48. Spicuzza L, Di Maria G, Polosa R. Adenosine in the airways: implications and applications. Eur. J. Pharmacol. 533, 77-88 (2006).
49. Klotz K-N, Falgner N, Kachler S et al. [3H] EMADO - a novel tritiated agonist selective for the human adenosine A3 receptor. Eur. J. Pharmacol. 556, 14-18 (2007).
50. Cho SY, Polster J, Engles JM, Hilton J, Abraham EH, Wahl RL. In vitro evaluation of adenosine 5́-monophosphate as an imaging agent of tumor metabolism. J. Nucl. Med. 47, 837-845 (2006).
51. Mathews WB, Nakamoto Y, Abraham EH et al. Synthesis and biodistribution of [11C] adenosine 5́-monophosphate ([11C]AMP). Mol. Imaging Biol. 7, 203-208 (2005).
52. Alauddin MM, Shahinian A, Park R, Tohme M, Fissekis JD, Conti PS. Biodistribution and PET imaging of [18F]-fluoroadenosine derivatives. Nucl. Med. Biol. 34, 267-272 (2007).
53. Alauddin MM, Fissekis JD, Conti PS. Synthesis of [18F]-labeled adenosine analogues as potential PET imaging agents. J. Labelled Cmpd. Radiopharm. 46, 805-814 (2003).
54. Nanni C, Di Leo K, Tonelli R et al. FDG small animal PET permits early detection of malignant cells in a xenograft murine model. Eur. J. Nucl. Med. Mol. I. 34, 755-762 (2007).
55. Kenny LM, Aboagye EO, Price PM. Positron emission tomography imaging of cell proliferation in oncology. Clin. Oncol. 16, 176-185 (2004).
56. Lehel Sz, Horváth G, Boros I, Mikecz P, Márián T, Trón L. Synthesis of 5́-deoxy-5́-[18F]fluoro-adenosine by radiofluorination of 5́-deoxy-5́-haloadenosine derivates. J. Radioanal. Nucl. Chem. 245, 399-401 (2000).
57. Lehel SZ, Horváth G, Boros I, Márián T, Trón L. The nucleophilic substitution reaction for [18F]fluoride-ion on the series of N6-benzoyl-2́,3́-isopropylideneadenosine-5́-sulfonates. J. Radioanal. Nucl. Chem. 251, 413-416 (2002).
58. Antoni G, Omura H, Ikemoto M, Moulder R, Watanabe Y, Långström B. Enzyme catalysed synthesis of l-[4-11C]aspartate and l-[5-11C] glutamate. J. Labelled Cmpd. Radiopharm. 44, 287-294 (2001).
59. Lui E, Chirakal R, Firnau G. Enzymatic synthesis of (-)-6-[18F]- fluoronorepinephrine from 6-[18F]-fluorodopamine by dopamine β-hydroxylase. J. Labelled Cmpd Radiopharm. 41, 503-521 (1998).
60. Bjurling P, Antoni G, Watanabe Y, Långström B. Enzymatic synthesis of carboxy-11C-labelled l-tyrosine, l-DOPA, l-tryptophan and 5-hydroxy-l-tryptophan. Acta Chem. Scand. 4, 178-182 (1990).
61. Cadicamo CD, Courtieu J, Deng H, Meddour A, O'Hagan D. Enzymatic fluorination in Streptomyces cattleya takes place with an inversion of configuration consistent with an SN2 reaction mechanism. ChemBioChem 5, 685-690 (2004).
62. Martarello L, Schaffrath C, Deng H, Gee AD, Lockhart A, O'Hagan D. The first enzymatic method for C-F-18 bond formation: the synthesis of 5́-[F-18]-fluoro-5́-deoxyadenosine for imaging with PET. J. Label. Cmpd Radiopharm. 46, 1181-1189 (2003).
63. Deng H, Cobb SL, McEwan AR et al. The fluorinase from Streptomyces cattleya is also a chlorinase. Angew. Chemie Int. Ed. 45, 759-762 (2006).
64. Deng H, Cobb SL, Gee AD et al. Fluorinase mediated C-18F bond formation, an enzymatic tool for PET labelling. Chem. Commun. 652-654 (2006).
65. Cobb SL, Deng H, McEwan AR, Naismith JH, O'Hagan D, Robinson DA. Substrate specificity in enzymatic fluorination. The fluorinase from Streptomyces cattleya accepts 2́-deoxyadenosine substrates. Org. Biomol. Chem. 4, 1458-1460 (2006).
66. Winkler M, Domarkas J, Schweiger LF, O'Hagan D. Fluorinase-coupled base swaps: synthesis of [18F]-5́-deoxy-5́-fluorouridines. Angew. Chem. Int. Ed. 47, 10141-10143 (2008).
67. O'Hagan D, Deng H, Schaffrath C. Fluorometabolite biosynthesis and the fluorinase from Streptomyces cattleya. Nat. Prod. Rep. 21, 773-784 (2004).
68. Onega M, McGlinchey RP, Deng H, Hamilton JTG, O'Hagan D. The identification of (3R,4S)-5-fluoro-5-deoxy-d-ribulose-1-phosphate as an intermediate in fluorometabolite biosynthesis in Streptomyces cattleya. Bioorg. Chem. 35, 375-385 (2007).
69. Deng H, Cross SM, McGlinchey RP, Hamilton JTG, O'Hagan D. In vitro reconstituted biotransformation of 4-fluorothreonine from fluoride ion: application of the fluorinase. Chem. Biol. 15, 1268-1276 (2008).
70. Drager G, Kiss C, Kunz U, Kirschning A. Enzyme-purification and catalytic transformations in a microstructured PASSflow reactor using a new tyrosine-based Ni-NTA linker system attached to a polyvinylpyrrolidinone-based matrix. Org. Biomol. Chem. 5, 3657-3664 (2007).